Form 4: BIOXYTRAN Director Boosts Stake with Stock Acquisitions

BIOXYTRAN Director Alan M. Hoberman reported multiple acquisitions of preferred and common stock in the company, increasing his direct beneficial ownership.

Summary

• Director Alan M. Hoberman acquired 10,417 shares of preferred stock at $0.485 per share on August 12, 2025, increasing his direct beneficial ownership to 377,619 preferred shares.
• On November 14, 2025, Mr. Hoberman acquired an additional 38,588 shares of preferred stock at $0.35 per share, bringing his direct beneficial ownership of preferred shares to 416,207.
• Mr. Hoberman purchased 210,000 shares of common stock at $0.6 per share on November 18, 2025, establishing a direct beneficial ownership of 210,000 common shares.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director is increasing their personal stake in the company, which typically indicates confidence in future performance. However, this is a single data point and not a comprehensive financial report.

Positives

• A director increasing their stake in the company through multiple stock acquisitions signals confidence in the company's future prospects.
• The acquisitions include both preferred and common stock, indicating a broad commitment to the company's equity.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

This Form 4 filing reports an insider transaction and does not provide broader industry context or trends.

Related Party Transactions

• Director Alan M. Hoberman, an insider, acquired preferred and common stock of BIOXYTRAN, INC.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive signal, potentially boosting investor confidence.
• The transactions demonstrate management's alignment with shareholder interests through direct equity ownership.

Key Dates

Recommendation

The director's multiple purchases of company stock, both preferred and common, are a positive signal, indicating management's confidence in BIOXYTRAN's future. While insider buying is generally a bullish indicator, a Form 4 filing alone does not provide sufficient comprehensive financial or operational data to warrant a 'buy' or 'strong buy' recommendation. Investors should consider this information as a supportive data point within a broader due diligence process, hence a 'hold' recommendation is appropriate pending further analysis of the company's fundamentals and market conditions.

Keywords

BIOXYTRAN, BIXT, Insider Trading, Form 4, Stock Acquisition, Director Ownership, Beneficial Ownership, Preferred Stock, Common Stock